L. Roca

发表

Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study

G. Romieu, W. Jacot, M. Fabbro, 2010, Breast Cancer.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

M. Pocard, D. Elias, D. Pezet, 2021, The Lancet. Oncology.

Two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC following complete cytoreductive surgery for colorectal carcinomatosis.

D. Elias, F. Dumont, F. Quénet, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2011, Familial Cancer.

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy

V. D’Hondt, W. Jacot, C. Touraine, 2021, Nutrients.

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study

V. D’Hondt, F. Goffin, G. Liberale, 2016, International Journal of Gynecologic Cancer.

A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7.

M. Pocard, D. Elias, D. Pezet, 2019, European Journal of Surgical Oncology.

A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.

M. Pocard, D. Elias, D. Pezet, 2018, Journal of Clinical Oncology.

Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options

M. Ychou, J. Duffour, E. Crapez, 2016, Journal of Genetic Counseling.

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

G. Romieu, P. Lamy, V. D’Hondt, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer

D. Laune, J. Duffour, F. Blanchard, 2014, Oncoimmunology.

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

S. Shak, F. Baehner, F. Penault-Llorca, 2014 .

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

Two‐stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second‐stage completion and longer survival☆

M. Ychou, P. Rouanet, O. Sgarbura, 2019, Surgery.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

J. Lemonnier, B. Asselain, M. Campone, 2017, European journal of cancer.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

G. Romieu, V. D’Hondt, W. Jacot, 2021, BMC cancer.

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

R. Gelber, D. Zardavas, M. Piccart-Gebhart, 2019, Breast Cancer Research and Treatment.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from digestive tract cancer—New management with oxaliplatin plus irinotecan: A feasibility study in 37 patients

M. Ychou, P. Rouanet, A. Gauthey, 2008 .

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

Results of Two Bi-Institutional Prospective Studies Using Intraperitoneal Oxaliplatin With or Without Irinotecan During HIPEC After Cytoreductive Surgery for Colorectal Carcinomatosis

D. Elias, F. Dumont, F. Quénet, 2011, Annals of surgery.

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2023, Breast Cancer Research and Treatment.

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

F. Pinguet, F. Dalenc, W. Jacot, 2015, BMC Cancer.

Clinical Impact of Intensified 5-Fluorouracil-Based Chemotherapy Using a Prospective Pharmacokinetically-Guided Dosing Approach: Comparative Study in Elderly and Non-Elderly Patients with Metastatic Colorectal Cancer

F. Pinguet, M. Ychou, J. Duffour, 2010 .

Limitations of the PRODIGE 7 trial - Authors' reply.

F. Quénet, D. Goéré, O. Glehen, 2021, The Lancet. Oncology.

A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).

S. Culine, L. Salomon, J. Bérille, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

S. Shak, F. Baehner, F. Penault-Llorca, 2018, BMC Cancer.

Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.

J. Lemonnier, P. Pujol, J. Fricker, 2020 .

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2012, Familial Cancer.

Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer.

F. Pinguet, M. Ychou, J. Duffour, 2010, Journal of chemotherapy.